| Literature DB >> 33178317 |
Jimei Xiao1, Jingyan Song1, Yuanhong Sa1, Lihua Yuan1, Jiayin Guo2, Zhengao Sun1,3.
Abstract
Diminished ovarian reserve (DOR) is the weakening of ovarian oocyte production and quality. It will further become premature ovarian failure without timely cure. However, disease pathology and diagnostic markers are still incompletely understood. Liu-Wei-Di-Huang (LWDH) pill, a traditional Chinese medicine formula, is commonly used in the treatment of DOR in China. To explore the mechanism of the effect of LWDH on in vitro fertilization (IVF) outcomes in patients with DOR, a pseudotargeted metabolomics study combined with multivariate data processing strategy was carried out. A liquid chromatography tandem mass spectrometry-based metabolomics approach was applied to characterize metabolic biomarker candidates. Multiple pattern recognition was used to determine groups and confirm important variables. A total of 21 potential biomarkers were characterized, and related metabolic pathways were identified. The study displayed that the established pseudotargeted metabolomics strategy is a powerful approach for investigating the mechanism of DOR and LWDH. In addition, the approach may highlight biomarkers and metabolic pathways and can capture subtle metabolite changes from headache, which may lead to an improved mechanism understanding of DOR diseases and LWDH treatment.Entities:
Year: 2020 PMID: 33178317 PMCID: PMC7648682 DOI: 10.1155/2020/5183017
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Clinical background of subjects.
| Item | Posttreatment | Pretreatment | Control |
|
|---|---|---|---|---|
| Age | 34.75 ± 3.47 | 32.97 ± 4.01 | 31.14 ± 3.38 | > 0.05 |
| Infertility years | 4.36 ± 2.16 | 3.66 ± 1.72 | 2.79 ± 1.62 | > 0.05 |
| BMI | 22.17 ± 1.70 | 21.42 ± 1.74 | 21.63 ± 1.34 | > 0.05 |
| Basic LH | 4.45 ± 1.62 | 4.69 ± 1.82 | 4.69 ± 1.78 | > 0.05 |
| Basic E2 | 48.43 ± 17.06 | 40.99 ± 20.43 | 38.45 ± 12.01 | > 0.05 |
| Basic P | 0.62 ± 0.29 | 0.74 ± 0.24 | 0.66 ± 0.21 | > 0.05 |
Total integral of pretreatment and posttreatment using LWDH pill.
| Item | Total integral | Coeffective |
|
|
|---|---|---|---|---|
| Pretreatment | 15.11 ± 3.119 | 0.765 | 13.811 | <0.001 |
| Posttreatment | 9.86 ± 2.445 |
∗The difference between the two groups was of detectable statistical significance.
The integral of each syndrome.
| Item | Pretreatment | Posttreatment | Coeffective |
|
|
|---|---|---|---|---|---|
| YaoXiSuanRuan | 3.21 ± 0.787 | 2.46 ± 1.427 | 0.403 | 3.000 | 0.006 |
| WuXinFanRe | 3.11 ± 0.567 | 1.29 ± 1.512 | 0.222 | 6.460 | <0.001 |
| KouGanYanZao | 1.14 ± 0.705 | 0.64 ± 0.678 | 0.575 | 4.415 | <0.001 |
| Dizziness | 1.18 ± 0.819 | 0.75 ± 0.441 | 0.231 | 2.714 | 0.011 |
| Emaciation | 0.32 ± 0.476 | 0.18 ± 0.39 | 0.677 | 2.121 | 0.043 |
| Forgetfulness | 0.43 ± 0.69 | 0.18 ± 0.39 | 0.668 | 2.553 | 0.017 |
∗The difference between the two groups was of detectable statistical significance.
The number of follicles and endocrine parameters during the day of hCG.
| Item | Posttreatment | Pretreatment |
|
|---|---|---|---|
| <14 mm follicles | 3.75 ± 1.624 | 2.69 ± 1.775 | 0.022 |
| ≥14 mm follicles | 4.04 ± 1.453 | 3.14 ± 1.552 | 0.028 |
| LH | 7.23 ± 4.16 | 5.2 ± 4.77 | 0.093 |
| E2 | 1187.71 ± 712.681 | 1143.52 ± 700.787 | 0.814 |
| P | 1.17 ± 0.62 | 1.24 ± 0.66 | 0.681 |
| Number of oocytes | 3.75 ± 1.531 | 2.72 ± 1.412 | 0.011 |
| Number of transplantable embryos | 1.68 ± 1.124 | 0.97 ± 0.778 | 0.007 |
| Number of high-quality embryos | 0.32 ± 0.723 | 0.21 ± 0.412 | 0.464 |
| Oocyte acquisition rate (%) | 92.9% | 86.8% | 0.145 |
| IVF fertilization rate (%) | 73.9% | 52.5% | 0.007 |
| Clinical pregnancy rate (%) | 25% | 20.7% | 0.698 |
∗The difference between the two groups was of detectable statistical significance.
Figure 1The typical chromatograms of follicular fluid samples.
Figure 2The comparison spectrum of N-acetyltryptophan between the experimental and reference MS/MS spectrum.
Figure 3The partial least-squares discriminant analysis recognition based on the follicular fluid metabolomic profiling.
Figure 4The VIP scores of each potential biomarker to the discrimination between the pretreatment group and the posttreatment group.
Figure 5The hierarchical clustering heatmap of the potential biomarkers.
Figure 6The metabolic pathways related to DOR, as analyzed by MetaboAnalyst.